Pfizer Vaccine on Track for Regulatory Review in October

Pfizer CEO said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.
Pfizer’s potential vaccine is one of three backed by the U.S. that’s currently in late-stage testing.
The U.S.-based pharmaceutical giant has been working alongside German drugmaker BioNTech.
In July, Pfizer released promising data from its early-stage trial.